Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H8O3 |
| Molecular Weight | 176.1687 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(=O)OC2=C1C=CC(O)=C2
InChI
InChIKey=HSHNITRMYYLLCV-UHFFFAOYSA-N
InChI=1S/C10H8O3/c1-6-4-10(12)13-9-5-7(11)2-3-8(6)9/h2-5,11H,1H3
| Molecular Formula | C10H8O3 |
| Molecular Weight | 176.1687 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25852691
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25852691
Hymecromone (4-methylumbelliferone) is already approved drug in Europe and Asia where it is used to treat biliary spasm. It is used as choleretic and antispasmodic drugs and as a standard for the fluorometric determination of enzyme activity. The concomitant administration of Hymecromone with products, containing metoclopramide, leads to mutual decrease of their action. Due to a danger of diarrhea with subsequent hypokalemia, Hymecromone should be applied with caution to patients on cardiac glycosides therapy (in these cases the sensitivity to them is increased). Hymecromone can be administered simultaneously with otherspasmolytics and analgesics. Very rare allergic reactions, itching, erythema, rashes; diarrhea which normally disappears by reduction of dose or discontinuance of therapy.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of an enzyme assay for rapid assessment of Escherichia coli in seawaters. | 2002 |
|
| A sulfated proteoglycan is necessary for storage of exocrine secretory proteins in the rat parotid gland. | 2002 Aug |
|
| Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirus. | 2002 Aug 16 |
|
| Utilization of fluorogenic assay for rapid detection of Escherichia coli in acidic fruit juice. | 2002 Dec |
|
| Optimisation of an enzymatic method for beta-galactosidase. | 2002 Dec |
|
| Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of drugs. I: studies by in vivo constant infusion. | 2002 May |
|
| Tissue-specific regulation of canine intestinal and hepatic phenol and morphine UDP-glucuronosyltransferases by beta-naphthoflavone in comparison with humans. | 2002 May 1 |
|
| The importance of cysteine 126 in the human liver UDP-glucuronosyltransferase UGT1A6. | 2002 May 20 |
|
| Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. | 2002 Nov |
|
| A colorimetric and fluorometric microplate assay for the detection of microcystin-LR in drinking water without preconcentration. | 2002 Nov |
|
| 4-Methylumbelliferone induces the expression of membrane type 1-matrix metalloproteinase in cultured human skin fibroblasts. | 2002 Nov 15 |
|
| Inhibition of hyaluronan synthesis in Streptococcus equi FM100 by 4-methylumbelliferone. | 2002 Oct |
|
| Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. | 2002 Oct |
|
| Effects of bergamottin on human and monkey drug-metabolizing enzymes in primary cultured hepatocytes. | 2002 Sep |
|
| A 45-kDa midgut glycoprotein from Anopheles albimanus mosquito mediates the killing of trypanosomes. | 2002 Sep |
|
| [Effect of vegetotropic pharmacologic preparations of the motor-evacuatory function of the gallbladder in patients with chronic biliary tract pathology]. | 2003 |
|
| Polar organic solvent added to an aqueous solution changes hydrolytic property of lipase. | 2003 Aug |
|
| [A case of successful use of odeston in the diagnostics and treatment of biliary dysfunctional disorders]. | 2003 Dec |
|
| Inhibition of rat liver sulfotransferases SULT1A1 and SULT2A1 and glucuronosyltransferase by dietary flavonoids. | 2003 Dec |
|
| Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor. | 2003 Dec |
|
| Verapamil regulates activity and mRNA-expression of human beta-glucuronidase in HepG2 cells. | 2003 Dec |
|
| HNK-1-Reactive oligosaccharide, sulfate-O-3GlcAbeta1-4Xylbeta1-MU, synthesized by cultured human colorectal cancer cells. | 2003 Jan |
|
| Microtiter plate cellular assay for human steroid sulfatase with fluorescence readout. | 2003 Jul 15 |
|
| Glucuronidation of 4-methylumbelliferone and 4-hydroxybiphenyl and in vitro induction of UDP-glucuronosyltransferase 2B12-mRNA in precision-cut rat liver slices. | 2003 Jun |
|
| Cloning and characterization of two alpha-glucosidases from Bifidobacterium adolescentis DSM20083. | 2003 Mar |
|
| Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of xenobiotics II: Studies with isolated perfused rat liver. | 2003 Nov |
|
| A nonradioactive 96-well plate assay for screening of trans-sialidase activity. | 2003 Nov 15 |
|
| Cloning and expression of alpha-D-glucosidase and N-acetyl-beta-glucosaminidase from the periodontal pathogen, Tannerella forsythensis (Bacteroides forsythus). | 2003 Oct |
|
| Induction of rat hepatic and intestinal UDP-glucuronosyltransferases by naturally occurring dietary anticarcinogens. | 2003 Oct |
|
| Inhibition of influenza A virus sialidase activity by sulfatide. | 2003 Oct 23 |
|
| Biochemical and catalytic properties of an endoxylanase purified from the culture filtrate of Sporotrichum thermophile. | 2003 Sep 1 |
|
| Enhanced enzymatic hydrolysis of langostino shell chitin with mixtures of enzymes from bacterial and fungal sources. | 2003 Sep 1 |
|
| Structural requirements of hydroxylated coumarins for in vitro anti-Helicobacter pylori activity. | 2003 Sep-Oct |
|
| Mechanism of the hydrolysis of 4-methylumbelliferyl-beta-D-glucoside by germinating and outgrowing spores of Bacillus species. | 2004 |
|
| DNA damage in healthy term neonate. | 2004 Apr |
|
| Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. | 2004 Apr |
|
| Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. | 2004 Apr |
|
| Development of novel conductometric biosensors based on immobilised whole cell Chlorella vulgaris microalgae. | 2004 Apr 15 |
|
| Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. | 2004 Apr 2 |
|
| Molecular characterization of membrane type and ganglioside-specific sialidase (Neu3) expressed in E. coli. | 2004 Apr 30 |
|
| Identification of aryl-phospho-beta-D-glucosidases in Bacillus subtilis. | 2004 Jan |
|
| Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. | 2004 Jan 1 |
|
| Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. | 2004 Jan 30 |
|
| Risk factors for periodontitis in HIV patients. | 2004 Jun |
|
| Expression of chitinase-encoding genes in Bacillus thuringiensis and toxicity of engineered B. thuringiensis subsp. aizawai toward Lymantria dispar larvae. | 2004 Mar |
|
| Stability of the complexes of some lanthanides with coumarin derivatives. I. Cerium(III)-4-methyl-7-hydroxycoumarin. | 2004 Mar |
|
| Synthesis and biological activity of substituted 2,4,6-s-triazines. | 2004 Mar |
|
| Effects of dietary anticarcinogens and nonsteroidal anti-inflammatory drugs on rat gastrointestinal UDP-glucuronosyltransferases. | 2004 Mar-Apr |
|
| Aldehyde detection by chromogenic/fluorogenic oxime bond fragmentation. | 2004 May 21 |
|
| A novel efflux-recapture process underlies the mechanism of high-density lipoprotein cholesteryl ester-selective uptake mediated by the low-density lipoprotein receptor-related protein. | 2004 Sep |
Sample Use Guides
1 tablet 3 times daily during basic meals. The tablets are administered unchewed with a liquid.
Route of Administration:
Oral
4-Methylumbelliferone (4-MU/HYMECROMONE) inhibits hyaluronan synthesis and retards cancer spreading in experimental animals through mechanisms not fully understood. These mechanisms were studied in A2058 melanoma cells, MCF-7 and MDA-MB-361 breast, SKOV-3 ovarian and UT-SCC118 squamous carcinoma cells by analysing hyaluronan synthesis, UDP-glucuronic acid (UDP-GlcUA) content, and hyaluronan synthase (HAS) mRNA levels. The maximal inhibition in hyaluronan synthesis ranged 22-80% in the cell lines tested. Active glucuronidation of 4-MU produced large quantities of 4-MU-glucuronide, depleting the cellular UDP-GlcUA pool. The maximal reduction varied between 38 and 95%. 4-MU also downregulated HAS mRNA levels: HAS3 was 84-60% lower in MDA-MB-361, A2058 and SKOV-3 cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:22:29 GMT 2023
by
admin
on
Fri Dec 15 15:22:29 GMT 2023
|
| Record UNII |
3T5NG4Q468
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
735220
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
||
|
WHO-VATC |
QA05AX02
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
||
|
FDA ORPHAN DRUG |
732620
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
||
|
WHO-ATC |
A05AX02
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
||
|
FDA ORPHAN DRUG |
733820
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB08089MIG
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
C489431
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL12208
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
90-33-5
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
1401
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
m6164
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
17224
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
19026
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
DB07118
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
201-986-7
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
HYMECROMONE
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
5556
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | RxNorm | ||
|
3T5NG4Q468
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
9408
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
1891
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
C166696
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
D006923
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
100000092576
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
5280567
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
DTXSID8025670
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SOLVATE->ANHYDROUS | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
